июня 20, 2023
New Developments in Regulatory Review Requirements for Healthcare M&A Transactions
июня 8, 2023
Are You Ready? The New FDA Requirement for Diversity Action Plans in Drug and Device Clinical Investigations
мая 10, 2023
Talk im Turm – Parallel Import: ECJ Reboxing vs. Relabeling Decision
апреля 20, 2023
Revision of the EU Pharmaceutical Legislation - What To Expect
апреля 5, 2023
Restructuring Takeover – A Crash Course on Hot Topics in Healthcare Restructurings
марта 15, 2023
What You Need to Know About the USITC Investigation into a TRIPS Waiver for COVID-19 Diagnostics and Therapeutics
марта 13, 2023
Key Food and Beverage Issues: Challenges and Opportunities in 2023
февраля 23, 2023
MDLs: Judges, Defendants and Plaintiffs Too – Who Is Buzzing About What?
февраля 15, 2023
Healthcare Fraud Enforcement Update - What Does 2023 Hold?
января 31, 2023
Best Practices for UK & EU Fund Managers Raising Capital in the GCC
января 24, 2023
Year in Review for Drug and Device Advertising and Promotion: Lessons Learned From 2022 FDA Enforcement Letters and Other Key Developments
января 19, 2023
A New Year, A New Day - What’s Next for Healthcare Policy and Oversight in the New Congress